Fudan University: Lymphoma trials

The registry lists 27 Lymphoma studies with Fudan University as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 22Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• RGL-305+ Lymphoma + Exploratory Clinical StudyRecruitingNCT07006012Not applicable
• Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous TransplantationRecruitingNCT07001540Phase 2
• A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLRecruitingNCT06966154Phase 1/2
• An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaRecruitingNCT06517004Phase 1
• A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell LymphomaRecruitingNCT06341556Phase 2
• Orelabrutinib in the Treatment of HP-positive Gastric MALT LymphomaRecruitingNCT06228963Phase 2
• ZR-CHOP in DLBCL With Specific Gene AbnormalityRecruitingNCT05290337Phase 2
• Gene Abnormalities and Prognosis in Diffuse Large B-cell LymphomaStatus unknownNCT04825899
• A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma PatientsStatus unknownNCT04516655Phase 2
• Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma PatientsCompletedNCT04164368Phase 2
• Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03373019Phase 2
• Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma PatientsStatus unknownNCT03318835Phase 3
• Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHLStatus unknownNCT01914744Phase 2
• Dose-adjusted EPOCH-R in MYC Positive DLBCLTerminatedNCT01914718Phase 2
• Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCLStatus unknownNCT01804127Phase 2
• Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell LymphomaStatus unknownNCT01667302Phase 2
• Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell LymphomaTerminatedNCT01667289Phase 2
• IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin LymphomaStatus unknownNCT01333605Phase 2
• R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell LymphomaStatus unknownNCT01278602Phase 2
• Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOPStatus unknownNCT01210287Phase 2/3
• Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell LymphomaStatus unknownNCT00974324Phase 2
• New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell LymphomaStatus unknownNCT00933673Phase 2
• Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCLCompletedNCT00854568Phase 3
• L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell LymphomaCompletedNCT00854425Phase 2
• Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)Status unknownNCT00840385Phase 2
• Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT00568815Phase 2
• Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell LymphomaStatus unknownNCT00568607Phase 2